REVELATION BIOSCIENCES, INC. Net Income (Loss) Attributable to Parent, Diluted
REVELATION BIOSCIENCES, INC. (REVB) reported Net Income (Loss) Attributable to Parent, Diluted of -$757.64 thousand for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-10-29.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToParentDiluted · last filed 2021-10-29
- REVELATION BIOSCIENCES, INC. net income (loss) attributable to parent, diluted for the quarter ending 2021-09-30 was -$757.64K.
| Period end | Net Income (Loss) Attributable to Parent, Diluted 3 month | Net Income (Loss) Attributable to Parent, Diluted 9 month |
|---|---|---|
| 2021-09-30 | -$757.64K 10-Q · filed 2021-10-29 | -$910.59K 10-Q · filed 2021-10-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |